ASMB

Assembly Biosciences Inc

Add to Watchlist

Advanced Chart

31.210

-0.9(-2.803%)1D

Line

Candle

YTD

High

32.680

Open

32.110

VWAP

31.96

Vol

84.16K

Mkt Cap

413.97M

Low

30.9201

Amount

2.69M

EV/EBITDA(TTM)

Total Shares

6.35M

171.38M

EV/OCF(TTM)

P/S(TTM)

6.77

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

9.32M

+36.22%

-0.775

-48.68%

9.32M

+26.74%

-0.745

-52.55%

8.90M

-5.51%

-0.850

-27.35%

Estimates Revision

The market is revising No Change the revenue expectations for Assembly Biosciences, Inc. (ASMB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 60.63%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-23.85%

In Past 3 Month

Stock Price

Go Up

+60.63%

In Past 3 Month

4 Analyst Rating

24.96% Upside

Wall Street analysts forecast ASMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASMB is 39.00 USD with a low forecast of 29.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

24.96% Upside

Current: 31.210

Low

29.00

Averages

39.00

High

50.00

24.96% Upside

Current: 31.210

Low

29.00

Averages

39.00

High

50.00

Citizens JMP

Roy Buchanan

Outperform

initiated

$38

2025-09-24

Reason

Citizens JMP

Roy Buchanan

Price Target

$38

2025-09-24

initiated

Outperform

Reason

Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences with an Outperform rating and $38 price target. The firm believes the company's "strong early data point to likely best-in-class profiles" for both its oral candidates for treating herpes simplex virus is underappreciated at current share levels. Assembly's lead opportunity in treating recurrent genital herpes has blockbuster potential, the analyst tells investors in a research note.

Guggenheim

Buy

upgrade

$31 -> $39

2025-09-08

Reason

Guggenheim

Price Target

$31 -> $39

2025-09-08

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Assembly Biosciences to $39 from $31 and keeps a Buy rating on the shares. Following interim data from Assembly's Phase 1b study released last month that demonstrated "striking efficacy and a clean safety profile" for ABI-5366, the firm is increasing its view of the odds of success to 75% from 65% and increasing its assumed monthly price to $500 from $300 for what it calls "a potential blockbuster novel weekly or monthly treatment" for recurrent genital herpes.

H.C. Wainwright

Patrick Trucchio

initiated

$50

2025-08-18

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$50

2025-08-18

initiated

Reason

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences with a Buy rating and $50 price target. The firm sees potential for the company's clinical-stage antiviral pipeline to deliver "significant value" in collaboration with Gilead Sciences (GILD).

Guggenheim

Vamil Divan

Strong Buy

Initiates

$31

2025-03-25

Reason

Guggenheim

Vamil Divan

Price Target

$31

2025-03-25

Initiates

Strong Buy

Reason

Guggenheim initiated coverage of Assembly Biosciences with a Buy rating and $31 price target.

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-03-24

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-03-24

Reiterates

Hold

Reason

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2024-12-27

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2024-12-27

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Assembly Biosciences Inc (ASMB.O) is -9.61, compared to its 5-year average forward P/E of -1.88. For a more detailed relative valuation and DCF analysis to assess Assembly Biosciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.88

Current PE

-9.61

Overvalued PE

-0.27

Undervalued PE

-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.24

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.95

Undervalued EV/EBITDA

-1.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.05

Current PS

32.11

Overvalued PS

35.70

Undervalued PS

-13.60

Financials

Annual

Quarterly

FY2025Q2

YoY :

+12.81%

9.63M

Total Revenue

FY2025Q2

YoY :

-9.10%

-11.09M

Operating Profit

FY2025Q2

YoY :

-8.55%

-10.20M

Net Income after Tax

FY2025Q2

YoY :

-32.83%

-1.33

EPS - Diluted

FY2025Q2

YoY :

-2.09%

-16.76M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

-167.98

FCF Margin - %

FY2025Q2

YoY :

-18.94%

-105.94

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

14.7K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

20.1M

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 161.98% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

940.5K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

14.7K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

20.1M

USD

Months

ASMB News & Events

Events Timeline

2025-10-10 (ET)

2025-10-10

08:08:54

Assembly Biosciences unveils preliminary Phase 1b results for ABI-5366

2025-08-08 (ET)

2025-08-08

08:08:35

Assembly Biosciences reports interim results from phase 1b study of ABI-5366

2025-08-08

08:06:58

Assembly Biosciences announces pricing of $175M in equity financings

News

9.0

10-19NASDAQ.COM

IRON Strengthens, MNMD Offers Reassurance to Investors, Could NKTR Experience an Early Christmas?

9.0

10-10Newsfilter

Assembly Biosciences Unveils Interim Phase 1b Results for HSV Helicase-Primase Inhibitor ABI-5366 at the 38th IUSTI Europe Congress on Sexually Transmitted Infections

2.0

09-29Benzinga

4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance